Topic:

Cancer Vaccines

Latest Headlines

Latest Headlines

Regeneus gets green light to move personalized cancer vaccine into PhI

Australian biotech Regeneus is set to become the latest company to brave moving a personalized cancer vaccine into the clinic. The company picked up clearance from an ethics committee this week, clearing the last remaining obstacle between it and the start of an early-phase study.

U.K.'s PsiOxus scores $39M for colorectal cancer vaccine combo trial

Oxford-based PsiOxus closed a Series C financing round, scoring £25 million ($39 million) to advance its lead candidate, enadenotucirev, an oncolytic virus aimed at fighting colorectal tumors. The funding came from GlaxoSmithKline's VC unit and U.K. heavyweight investor Neil Woodford's new $1.2 billion fund.

NewLink continues cancer vaccine Ph III trial with interim data under wraps

Without convincing data to prove a win for NewLink Genetics' late-stage cancer vaccine, it will go full steam ahead on its Phase III trial, the company announced Monday. The IMPRESS trial for algenpantucel-L--or HyperAcute pancreas--will continue with no changes following the second planned interim analysis for the trial.

Aduro swings for the fences with $119M IPO

Aduro Biotech is picking up in 2015 where it left off last year, riding momentum into an upsized $119 million IPO to fund its breakthrough pancreatic cancer immunotherapy combo CRS-207 and GVAX.

Northwest Bio gets $40M more for controversial brain cancer vaccine

Back in November, U.K. heavyweight investor Neil Woodford invested $25 million in Northwest Biotherapeutics in the hope that its brain cancer candidate would turn up good Phase III results. Now, Woodford has thrown another $40 million behind the Bethesda, MD-based biotech as it continues to work through Phase III.

Germany's cost watchdog decides Valeant's Provenge has added benefit after all

In January, Germany's cost watchdog decided that Dendreon's--now Valeant's--Provenge had no added benefit for men with metastatic prostate cancer. But now, it's changing its tune.

Cancer vaccine maker Aduro files for $86M IPO

Aduro Biotech is the latest to try its hand at an IPO, and it laid out its case for an $86 million IPO last week.

Gates Foundation puts $52M behind CureVac, following Sanofi, Boehringer's lead

The Bill & Melinda Gates Foundation announced this week it's betting on CureVac, a move both Sanofi and Boehringer Ingelheim made last year, committing to an mRNA technology designed to make vaccines less expensive and easier to make.

Bristol-Myers bets $1B on Bavarian Nordic cancer vaccine

After a handful of large-scale monotherapy flops for cancer vaccines, many companies now think pairing them up as part of immunotherapy combos might be the way to go. And immuno-oncology pioneer Bristol-Myers Squibb just made a big bet that that's the case.

Aduro, BMS cancer vaccine combo to start Phase II

In another step forward for cancer vaccine combos, Aduro Biotech announced Thursday that an investigator-led Phase II trial of its GVAX and CRS-207 for pancreatic cancer with Opdivo, Bristol-Myers Squibb's PD-1 drug, would begin.